CG Oncology, Inc. Common stock (CGON) Stock Price
CGONStock
$59.85+43.01%52W
Market Cap$5.31B
P/E—
PEG Ratio—
Div yield—
Beta0.31
CGON Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-20.95%
Price vs S&P 500 (4W)-22.19%
VGM Score57.89
CGON Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.64 | -$0.90 | -40.06%(-$0.26) | |
| Q1 2026 | -$0.54 | -$0.71 | -31.53%(-$0.17) | |
| Q4 2025 | -$0.58 | -$0.51 | +12.57%(+$0.07) | |
| Q3 2025 | -$0.55 | -$0.57 | -4.26%(-$0.02) | |
| Q2 2025 | -$0.45 | -$0.54 | -20.09%(-$0.09) |
CGON Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.14
4.14
4.14
4.14
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
CGONCG Oncology, Inc. Common stock | F | A | B | 851.8x | 1030.3% | -85.2% | — | $59.85 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About CG Oncology, Inc. Common stock
CG Oncology is a late-stage biopharmaceutical company developing cretostimogene grenadenorepvec, an intravesical oncolytic immunotherapy for non-muscle-invasive bladder cancer. The candidate is in two Phase 3 trials targeting BCG-unresponsive and intermediate-risk patients, along with a Phase 2 study combining the therapy with checkpoint inhibition. The treatment aims to offer a bladder-sparing alternative to surgery for qualifying patients.